Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XAIR 
Beyond Air Inc (XAIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/10/2025: XAIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.25
1 Year Target Price $2.25
| 1 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.36% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.99M USD | Price to earnings Ratio - | 1Y Target Price 2.25 |
Price to earnings Ratio - | 1Y Target Price 2.25 | ||
Volume (30-day avg) 5 | Beta 0.23 | 52 Weeks Range 0.15 - 0.68 | Updated Date 07/1/2025 |
52 Weeks Range 0.15 - 0.68 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-18 | When - | Estimate -0.122 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) -622.74% |
Management Effectiveness
Return on Assets (TTM) -63.97% | Return on Equity (TTM) -233.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20638906 | Price to Sales(TTM) 4.32 |
Enterprise Value 20638906 | Price to Sales(TTM) 4.32 | ||
Enterprise Value to Revenue 5.57 | Enterprise Value to EBITDA -4.23 | Shares Outstanding 92794800 | Shares Floating 67016388 |
Shares Outstanding 92794800 | Shares Floating 67016388 | ||
Percent Insiders 13.41 | Percent Institutions 20.73 |
Analyst Ratings
Rating 3 | Target Price 2.25 | Buy 3 | Strong Buy 1 |
Buy 3 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Beyond Air Inc
Company Overview
History and Background
Beyond Air, Inc. was founded to develop and commercialize innovative nitric oxide (NO) generator and delivery systems using its proprietary LungFit technology. It focuses on treating respiratory diseases and conditions.
Core Business Areas
- LungFit PH: The LungFit PH system is Beyond Air's lead product, designed to deliver inhaled nitric oxide (iNO) to treat persistent pulmonary hypertension of the newborn (PPHN).
- LungFit GO: LungFit GO is a portable NO generator being developed for use in various settings, including home and ambulance use. Aims to treat lung infections that are resistant to other treatments.
Leadership and Structure
Beyond Air's leadership includes Steve Lisi (Chairman & CEO), Douglas Larson (Chief Financial Officer), and other key management personnel. The company has a board of directors responsible for governance.
Top Products and Market Share
Key Offerings
- LungFit PH: LungFit PH is the primary commercial product. It delivers iNO for PPHN treatment. Market share data specific to LungFit PH is difficult to determine due to limited available data. Competitors include Mallinckrodt's INOmax. Revenue from this product is the company's primary revenue source.
- LungFit GO: LungFit GO is under development and not yet commercially available. Once approved, it will address a broader range of respiratory conditions. There are not any similar devices currently on the market.
Market Dynamics
Industry Overview
The industry involves medical devices for respiratory therapy, specifically focusing on inhaled nitric oxide delivery. This segment caters to neonatal care, critical care, and potentially outpatient settings. iNO delivery is used to treat pulmonary hypertension and other respiratory ailments. There are other treatment methods, for example, other inhaled medications.
Positioning
Beyond Air is positioning itself as an innovator in iNO delivery with its LungFit technology. A potential competitive advantage lies in its ability to generate NO from ambient air, potentially offering cost and logistical benefits. iNO is a specialized medical treatment.
Total Addressable Market (TAM)
The TAM for iNO delivery is estimated to be significant, driven by the prevalence of PPHN and other respiratory conditions. Specific figures vary depending on the analysis and geographical scope, but easily exceed one billion USD. Beyond Air is positioned with the LungFit PH to capture part of the PPHN market. The LungFit GO is intended to increase TAM by expanding the number of treatable condidtions.
Upturn SWOT Analysis
Strengths
- Proprietary LungFit technology
- Potential for cost-effective NO generation
- Focus on unmet needs in respiratory care
- Compact NO generating technology
Weaknesses
- Limited commercial track record
- Dependence on regulatory approvals
- Need for additional funding
- Relatively small company compared to established players
Opportunities
- Expansion into new indications (e.g., viral pneumonia)
- Strategic partnerships
- Global market expansion
- Development of next-generation NO delivery systems
Threats
- Competition from established players
- Changes in reimbursement policies
- Clinical trial failures
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MALL (Mallinckrodt)
- LIN (Linde)
Competitive Landscape
Beyond Air is a smaller player compared to Mallinckrodt and Linde. Its advantages lie in its innovative technology and potential for cost-effective NO delivery. However, it faces challenges in competing with the established market presence and resources of larger companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recent commercialization of LungFit PH. There is no prior revenue to show prior to LungFit PH being on the market.
Future Projections: Future growth is dependent on the successful commercialization of LungFit PH and the development and approval of LungFit GO. Analyst projections vary.
Recent Initiatives: Recent initiatives include expanding the sales and marketing efforts for LungFit PH and continuing clinical trials for LungFit GO.
Summary
Beyond Air is an innovative company focused on respiratory therapies with a proprietary technology. While its LungFit PH is commercially available, the company still relies on regulatory approvals and faces competition from larger companies. Its financial position requires continued investment and strategic execution for long-term success. LungFit GO also needs to be approved and this is a key element to their strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available - not used for numerical data where unavailable)
- Published Medical Literature
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Financial performance data may be dated and incomplete. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beyond Air Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 2017-09-22 | CEO & Chairman of the Board Mr. Steven Adam Lisi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 61 | Website https://www.beyondair.net |
Full time employees 61 | Website https://www.beyondair.net | ||
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.